Carbapenems
Regulatory activity · MHRAAlso known as (5r)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, (5r)-carbapenem, (5r)-carbapenem-3-carboxylic acid, Antibiotic tan 458+3 more
(5r)-7-oxo-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, (5r)-carbapenem, (5r)-carbapenem-3-carboxylic acid, Antibiotic tan 458, Carbapenem, Carbapenem, (5r)-, 1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid, 7-oxo-, (5r)-.
Recent clinical, regulatory, research and industry developments relating to this drug.
Epidemiology and Diagnostics of Carbapenem Resistance in Gram-negative Bacteria.
Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections.
Drug Safety Update: Carbapenems: concomitant use with valproic acid not recommended
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Contains public sector information from the Medicines and Healthcare products Regulatory Agency (MHRA) licensed under the Open Government Licence (OGL v3).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes5
Journals, researchers & institutions
- Clinical infectious diseases : an official publication of the Infectious Diseases Society of America3
- Genome medicine1
- MMWR. Morbidity and mortality weekly report1
- Aitken SL1
- Arias J1
- Bonomo RA1
- Chew D1
- Clancy CJ1
- Deng Z1
- Doi Y1
- Greeley R1
- Center for Innovative Antimicrobial Therapy1
- Fujita Health University School of Medicine1
- Institut National de la Santé et de la Recherche Médicale European Unit1
- Institute for Microbiology1
- Institute of Antibiotics1
- Johns Hopkins University School of Medicine1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.